Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACTR-087/SEA-BCMA-combination-therapy (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 04 Nov 2019 According to an Unum Therapeutics media release, two additional cohorts of patients have been treated in this study ( escalating doses : SEA-BCMA to 2.0 mg/kg and ACTR087+ T cells to 50M ). The company have suspended the further dose-escalation of the study.
    • 28 Mar 2019 According to an Unum Therapeutics media release, company expects to continue to enroll and dose patients through the dose escalation phase of the trial and to report data from multiple dose cohorts in the second half of 2019.
    • 28 Mar 2019 According to an Unum Therapeutics media release, Enrollment at Dose Level 4 (30 MM ACTR+ T cells and 2.0 mg/kg SEA-BCMA) is ongoing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top